Abstract
PD-1/PD-L1 inhibitors as neoadjuvant therapy have shown promising anti-tumor activities in patients with early-stage non-small cell lung cancer (NSCLC). Here, we designed a phase II, single-arm trial to explore the antitumor activity, safety, and feasibility of neoadjuvant toripalimab plus double platinum-based chemotherapy in treatment-naive patients with potentially resectable NSCLC (ClinicalTrials.gov: NCT04144608).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have